Introduction {#s1}
============

The early diagnosis of 21-hydroxylase deficiency (21-OHD) is mandatory for both correct sexual assignment and early treatment to prevent adrenal crisis. In term infants, 17α-hydroxyprogesterone (17-OHP) in a filter paper-dried blood spot has proven to be useful in newborn mass-screening for 21-OHD. Serum levels of 17-OHP are very sensitive markers for biochemical diagnosis of 21-OHD; however, in premature infants no marker for biochemical diagnosis of 21-OHD has been found. In preterm infants, 17-OHP is not useful because of interference by delta 5 steroids from the fetal adrenal cortex. The serum levels of 17-OHP can be high in unaffected preterm infants, precluding the biochemical diagnosis of 21-OHD ([@r1],[@r2],[@r3],[@r4]).

We present here a case of a female infant with 21-OHD, born at 31 wk of gestation. Analysis of urinary steroid profiles by gas chromatography/mass spectrometry in selected ion monitoring (GCMS-SIM) showed a high pregnanetriolone (Ptl) level, which was strongly suggestive of 21-OHD. The diagnosis of 21-OHD was confirmed by gene analysis of *CYP21A2*. This is the first report which presents the usefulness of urinary Ptl by GCMS-SIM for the biochemical diagnosis of 21-OHD in preterm infants.

Case Report {#s2}
===========

A female Japanese infant was born to unrelated parents, as the first child of trichorionic, triamniotic triplets. None of her family had 21-OHD. She was delivered at 31 wk of gestation by an emergency cesarean section because of preterm labor; the birth weight was 1,464 g and the Apgar score was 6 and 8 at 1 and 5 min, respectively. Mechanical ventilation and medical treatment were required for respiratory distress syndrome, patent ductus arteriosus, and heart failure. Phototherapy was given from 3 through 6 and from 8 through 11 d of age for hyperbilirubinemia. At 5 d of age, we found mild clitoromegaly as well as pigmentation of the tongue and gingiva. Laboratory data and imaging studies revealed hyponatremia (127 mEq/l), hyperkalemia (7.7 mEq/l), disseminated intravascular coagulopathy (DIC), pulmonary hemorrhage, and subependymal hemorrhage. Medical treatment successfully controlled the respiratory failure, heart failure, and DIC. A provisional diagnosis of 21-OHD was made, prompting us to do endocrinological studies: 17-OHP \>93.5 (ELISA 7 prime extractive method in filter paper-dried blood spot) and 718.3 ng/ml (RIA after high performance liquid chromatography extraction in serum); plasma ACTH 690 pg/ml; plasma renin activity 77.4 ng/ml/h; serum 21-deoxycortisol (21-DOF) 368 ng/ml; serum androstenedione 292 ng/ml; and serum testosterone 3,169 ng/dl. Ultrasonography found bilaterally enlarged adrenal glands. Urine steroid profile analysis was performed according to the method previously reported ([@r5]). In brief, the method consisted of enzymatic hydrolysis of 0.5--2 ml of urine sample, extraction, derivative formation, purification, GCMS-SIM analysis and quantification. The urinary steroid profiles at 8 d of age showed a high Ptl level (0.80 mg/g creatinine; [Table 1](#tbl_001){ref-type="table"}Table 1Urinary steroid profile by GCMS-SIM at 8 d of age). This high level of Ptl strongly suggested 21-OHD when correlated with the cut-off level in term infants. We analyzed *CYP21A2* gene on the patient and her parents with genomic DNA extracted from their peripheral blood leukocytes by PCR direct sequencing ([@r6]). Informed consent for gene analaysis was obtained from her parents. The patient had compound heterozygosity, one allele having a cluster mutation in exon 6 (I236K, V237E, M239K) and the other having a large deletion including *CYP21A2*. Each parent had heterozygous abnormality. The diagnosis of 21-OHD was confirmed by these results.

Discussion {#s3}
==========

The biochemical diagnosis of 21-OHD was made by the finding of a high urinary Ptl level that had been determined via GCMS-SIM in this preterm infant. The level of Ptl was compatible with 21-OHD previously reported in term infants ([@r7]). The diagnosis was ultimately confirmed by molecular analysis.

In premature infants, the diagnosis of 21-OHD is difficult because: \[1\] Preterm infants with 21-OHD may have subtle ambiguous genitalia due to prematurity of the labia majora pudenda; \[2\] Preterm infants without 21-OHD often show hyponatremia and hyperkalemia, which are common laboratory findings in 21-OHD; \[3\] Although gene analysis of *CYP21A2* is a good test for the diagnosis of 21-OHD, it is time consuming and expensive ([@r8]); \[4\] Most importantly, a marker for the biochemical diagnosis of 21-OHD has not been found. In preterm infants, 17-OHP is not useful because of the interference of delta 5 steroids from the fetal adrenal cortex. An unaffected preterm infant may have high serum levels of 17-OHP ([@r1],[@r2],[@r3],[@r4]). Gruneiro-Papendieck *et al.* reported 17-OHP levels had a statistically significant negative correlation with gestational age and birth weight ([@r9]). In newborn mass-screening for 21-OHD, a modification of the cut-off limits of 17-OHP in a filter paper-dried blood spot has been reported; this modification has been found to have slightly increased specificity in preterm infants. Allen *et al.* reported weight-adjusted criteria for 17-OHP to reduce the false-positive rate of 21-OHD in preterm infants ([@r10]). Their weight-adjusted criteria, however, do not factor in small for gestational age infants. Ohkubo *et al.* reported cut-off limits allowing for the equivalent age of gestation at blood sampling ([@r11]). This method may prove to be useful for screening, but cannot provide a definitive diagnosis.

Urinary steroid profiles, especially Ptl, by GCMS-SIM can be useful for the biochemical diagnosis of 21-OHD in preterm infants because: \[1\] they can detect a full spectrum of steroid hormone metabolites ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1Chief steroid metabolites in 21-OHD. Urinary steroid profiles obtained by GCMS-SIM can detect all urinary metabolites shown here. P5: pregnenolone. P4: progesterone. B: corticosterone. A: 11-dehydrocorticosterone. S: deoxycortisol. F: cortisol. E: cortisone. Ald: aldosterone. 11HP5: 17α-hydroxypregnenolone. 17HP4: 17α-hydroxyprogesterone. DOC: deoxycorticosterone. 21-DOF: 21-deoxycortisol. 21-DOE: 21-deoxycortisone. DHEA: dehydroepiandrosterone. A4: androstenedione. 11HA4: 11 hydroxyandrostenedione. 16HP5: 16α-hydroxypregnenolone. PT: pregnanetriol. Ptl: pregnanetriolone. 16αHD: 16α-hydroxyDHEA. THE: tetrahydrocortisone. An: androsterone 11HA: 11*β*-hydroxyandrosterone); \[2\] the sample collection is noninvasive and a random sample is appropriate; \[3\] reference values of urinary steroids in term newborn infants by GCMS-SIM have been established ([@r5]); \[4\] precursor/product ratio assessments can be measured, which may increase both the sensitivity and specificity of the diagnosis ([@r7]). The literature contains reports that describe urinary steroid profiles by GCMS-SIM for the biochemical diagnosis of 21-OHD in newborn infants. Via urinary steroid profiles with GCMS-SIM, Malunowicz *et al.* studied 161 newborns and infants, with clinical suspicion of congenital adrenal hyperplasia (CAH). In eight cases (two full-term and six preterm infants), a false-positive diagnosis of CAH was made based on serum steroid evaluation ([@r12]). Caulfield *et al.* reported three diagnostic ratios, measured by GCMS-SIM: 17α-hydroxypregnanolone × 100/cortisol metabolites (CM); pregnanetriol (PT) × 100/CM; and Ptl × 100/CM having no overlap between 21-OHD and normal infants ([@r7]).

Among several metabolites of 17-OHP, urinary Ptl may be the best biochemical marker for the diagnosis of 21-OHD in term infants. Ptl exhibited no overlap between the 21-OHD cases and the control when we compared several urinary steroid metabolites by means of GCMS-SIM ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2Urine pregnanetriolone (Ptl) in the patient, 21-OHD, and control. Ptl levels measured by GCMS-SIM in term control infants (number=29, 6--14 d of age), term infants with 21-OHD (number=28, 7--14 d of age), and our patient (8 d of age). There was no overlap between the control and 21-OHD. The level of Ptl in our patient was beyond that of control infants.). Other metabolites, such as PT and androsterone, exhibited overlap between the control and 21-OHD (data not shown). The mechanisms which explain why Ptl is superior to PT, in the early biochemical diagnosis of 21-OHD, despite the fact that both are specific metabolites of 21-OHD ([Fig. 1](#fig_001){ref-type="fig"}), are not completely understood. One possible reason for the disparity may be because of a relatively greater inactivity of the enzymes metabolizing 17-OHP to PT than 21-DOF to Ptl in newborns.

In preterm infants, urinary Ptl with GCMS-SIM may have good sensitivity and specificity for the biochemical diagnosis of 21-OHD. Our study suggests that urinary Ptl with GCMS-SIM may have the ability to make a biochemical diagnosis of 21-OHD (true positive). It is of note that Furukawa *et al.* reported urinary Ptl levels obtained by GCMS-SIM were helpful in diagnosing two very low birth weight infants as having transient high 17-OHP (43.6 and 27.7 ng/ml at 35 and 10 d of age, respectively) and transient high 21-DOF (6.0 and 4.2 ng/ml at 35 and 16 d of age, respectively) (false positive) ([@r13]).

Finally, we propose that the measurement of urinary Ptl by GCMS-SIM is a useful biochemical marker for the diagnosis of 21-OHD even in preterm infants. We recommend all neonatologists and pediatricians to measure urinary Ptl by GCMS-SIM in any premature infants who have high 17-OHP with filter paper-dried blood spot in newborn screening. Additional premature infant case studies are indicated to establish and confirm the usefulness of urinary Ptl by GCMS-SIM.
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